A preventive treatment for dementia has shown remarkable promise in mouse studies. Human clinical trials could begin soon.
In France, Alzheimer's—the most common form of dementia—affects three million people directly or indirectly, and nearly 50 million worldwide. Despite extensive research, the disease remains poorly understood, making it challenging to treat and currently incurable.
Two key pathological processes are well-established: the accumulation of beta-amyloid peptides in the brain, and the transformation of Tau proteins into abnormally phosphorylated, aggregated forms. Together, these drive progressive neuronal degeneration.
Recent efforts to clear amyloid and tau aggregates have largely failed, shifting focus toward prevention—stopping these toxic proteins from forming in the first place. Preclinical data also indicate that amyloid and tau interact synergistically to trigger neurodegeneration, underscoring the need for combined targeting.
Researchers from the Institute for Molecular Medicine (USA) and Flinders University (Australia) have advanced this approach. In a study published in Alzheimer’s Research & Therapy, they describe a dual-vaccine strategy. One vaccine generates antibodies to block amyloid aggregation, the other targets tau.
"These vaccines train the immune system to produce antibodies that recognize and dismantle these abnormal protein clumps," the researchers explain.
The vaccines—AV-1959R and AV-1980R—were tested in mice engineered to mimic dementia. Results showed they not only prevented protein aggregations but also significantly reduced existing ones.
This suggests dual potential as both preventive and therapeutic agents, at least in preclinical models. The team is now preparing for first-in-human trials, potentially within the next two years.
Source
Related articles:
